Última actualização :
19/11/2024
droga contra o câncer   Trastuzumab  
injetável
Estabilidade em soluções simples Estabilidade em misturas Factores que afectam a sua estabilidade Compatibilidade Método de administração Bibliografía pdf

Nomes comerciais nos diversos países   Nomes comerciais nos diversos países     

OS NOMES COMERCIAIS SÃO INDICATIVOS E OS EXCIPIENTES DA FORMULAÇÃO PODEM SER DIFERENTES CONFORME O PAÍS E FABRICANTE.

Herceptin Alemanha, Arábia Saudita, Argentina, Australia, Austria, Bélgica, Brasil, Canadá, Chilli, Colômbia, Dinamarca, Egipto, Emirados Árabes Unidos, Equator, Espanha, Estados Unidos de América, Finlandia, França, Gran-bretanha, Grècia, Hungria, Irã, Irlanda, Islandia, Itália, Japón, Luxemburgo, Malásia, Marrocos, México, Noruega, nova Zelândia, Países Baixos, Peru, Polonia, Portugal, Romènia, Suècia, Suicia, Turquia
Herclon Peru
Hertraz Chilli
Herzuma Alemanha, Bélgica, Espanha, Estados Unidos de América, França, Gran-bretanha
Kanjinti Alemanha, Bélgica, Espanha, Gran-bretanha
Trastuzumab Baxter nova Zelândia
Trazimera Gran-bretanha
Bibliografía   injetável   Bibliografía : Trastuzumab  
tipo publicação
2296 Laboratório Témocilline (Negaban®) - Résumé des caractéristiques du produit
Eumedica 2017
2975 poster Nalenz H, Schoenhammer K, Dietel E, Heynen S.R, Grauschopf U, Mahler H.C.
In-Use stability of herceptin for subcutaneous injection with different administration materials.
ESCP 2014 2014
3077 Laboratório Trastuzumab (Herceptin®) – Summary of Product Characteristics
Roche 2019
3113 livro Herceptin
Compendium Suisse des m?dicaments 2010
3258 jornal Kaiser J, Krämer I.
Physicochemical Stability of Diluted Trastuzumab Infusion Solutions in Polypropylene Infusion Bags.
Int J Pharm Compound 2011 ; 15, 6 : 515-520.
3343 poster Vieillard V, da Silva R, Astier A, Paul M.
Physicochemical stability of diluted trastuzumab solutions stored 6 months at 4°C.
ECOP Congress, Budapest, Hungary 2012
3366 jornal Kwong Glover Z.W, Gennaro L, Yadav S, Demeule B, Wong P.Y, Sreedhara A.
Compatibility and stability of pertuzumab and trastuzumab admixtures in i.v. infusion bags for coadministration.
J Pharm Sci 2012 ; DOI 10.1002 / jps.23403
3386 jornal Paul M, Vieillard V, Da Silva Lemos R, Escalup L, Astier A.
Long-term physico-chemical stability of diluted trastuzumab.
Int J Pharm 2013 ; 448: 101-104.
3647 Laboratório Trastuzumab (Herceptin® 600 mg for subcutaneous injection) - Summary of Product Characteristics
Roche 2019
3849 jornal Pabari R.M, Ryan B, Ahmad W, Ramtoola Z.
Physical and structural stability of the monoclonal antibody, trastuzumab (Herceptin®), intravenous solutions.
Curr Pharm Biotech 2013 ; 14, 2: 220-225.
4163 jornal Nalenz H, K?pf E, Dietel E.
Prolonged In-Use Stability of Reconstituted Herceptin in Commercial Intravenous Bags.
Int J Pharm Compound 2018 22;5:417-423
4191 jornal Vieillard V, Astier A, Paul M.
Extended stability of a biosimilar of trastuzumab (CT-P6) after reconstitution in vials, dilution in polyolefin bags and storage at varioustemperatures.
GaBI Journal 2018
4194 jornal Kim S.J, Lee J.W, Kang H.Y, Kim S.Y, Shin Y.K, Kim K.W, Oh J.S, Lim K.J, Kim J.Y.
In-Use Physichochemical and Biological Stability of the Trastuzumab Biosimilar CT-P6 Upon Preparation for Intravenous Infusion.
Bio Drugs 2018 32;619-625
4271 jornal Yun J, Kim J, Chung J, Hwang S-J, Park S-J.
Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties
Adv Ther 2019
4396 jornal Lueras A, Polozova A, Asbury D, Hippenmeyer J, Litowski J, Goss M, Breslin P, Crampton S.
Stability of the trastuzumab biosimilar ABP 980 compared to reference product after intravenous bag preparation, transport and storage at various temperatures, concentrations and stress conditions.
GaBI Journal 2020 ; 9, 1:
4477 jornal Crampton S, Polozoxa A, Asbury D, Lueras A, Breslin P, Hippenmeyer J, Litkowski J,,Goss M.
Stability of the trastuzumab biosimilar ABP 980 compared to reference product after intravenous bag preparation, transport and storage at various temperatures, concentration and stress conditions.
GaBI Journal 2020 ; 9, 1: 5-13.
4493 jornal Le Guyader G, Vieillard V, Paul M.
Physicochemical stability study of MYL-1401O, a biosimilar of trastuzumab, following a transient temperature excursion.
J Oncol Pharm Practice 2020
4649 jornal Davies L, Milligan K, Corris M, Clarke I, Dwyer P, Lee S-E, Teraoka J, Crouse-Zeineddini J, Hippenmeyer J.
Extended stability of the trastuzumab biosimilar ABP 980 (KANJINTI™) in polyolefin bags and elastomeric devices.
GaBI Journal 2021 ; 10, 4
4754 jornal Weiser S, Burns C, Zartler E
Physicochemical stability of PF-05280014 (trastuzumab-qyyp; TrazimeraTM), a trastuzumab biosimilar, under extended in-use conditions.
J Oncol Pharm Practice 2023 ;29,3:

  Mentions Légales